| Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose. | |
| | |
MedLine Citation:
|
PMID: 20708814 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To determine whether altered GLP-1 activity contributes to the abnormal endogenous glucose production (EGP) and insulin secretion characteristic of people with impaired fasting glucose (IFG). METHODS: People with IFG (n=10) and normal glucose tolerance (NGT; n=13) underwent assessment of EGP (via [6,6-(2)H(2)]-glucose infusion). Parameters of whole body insulin action and secretion were estimated by IVGTT and OGTT. Measures of EGP and insulin secretion were made before and after sitagliptin administration. RESULTS: EGP was not different at baseline (glucose R(a); 1.47+/-0.08 vs. 1.46+/-0.05mg/kg/min, IFG vs. NGT, p=0.93). However, when differences in circulating insulin were accounted for (EGPXSSPI; 20.2+/-2.1 vs. 14.4+/-1.0AU, vs. NGT, p=0.03) the hepatic insulin resistance index was significantly higher in IFG. Baseline insulin action (S(i); 2.3+/-0.1x10(-4)/microU/ml vs. 3.5+/-0.4x10(-4)/microU/ml, p=0.01, IFG vs. NGT) and secretion (DI; 587+/-81x10(-4)/min vs. 1171+/-226x10(-4)/min, p=0.04, IFG vs. NGT) were impaired in IFG when evaluated by the IVGTT, but not by OGTT (insulin sensitivity 4.52+/-1.08x10(-4)dl/kg/min vs. 6.73+/-1.16x10(-4)dl/kg/min, IFG vs. NGT, p=0.16; indices of basal (Phi(b)), static (Phi(s)), dynamic (Phi(d)), and total (Phi(t)) insulin secretion, p>0.07). Sitagliptin did not change EGP or insulin secretion in either group. CONCLUSIONS: Incretin action maintained insulin secretion, but not hepatic insulin action, in people with IFG. |
| | |
Authors:
|
Leigh Perreault; Chiara Dalla Man; Devon M Hunerdosse; Claudio Cobelli; Bryan C Bergman |
Related Documents
:
|
2340794 - Diabetes and impaired glucose tolerance in an asian community in tanzania. 14578254 - The metabolic syndrome as predictor of type 2 diabetes: the san antonio heart study. 16924274 - Metabolic characteristics of patients with apparently normal fasting plasma glucose. 18084674 - Diabetes and impaired glucose regulation in first-degree relatives of patients with typ... 2449974 - Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of... 19553624 - Abnormal retinal vascular oxygen tension response to light flicker in diabetic rats. |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-08-13 |
Journal Detail:
|
Title: Diabetes research and clinical practice Volume: 90 ISSN: 1872-8227 ISO Abbreviation: Diabetes Res. Clin. Pract. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-06 Completed Date: 2011-01-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8508335 Medline TA: Diabetes Res Clin Pract Country: Ireland |
Other Details:
|
Languages: eng Pagination: 87-94 Citation Subset: IM |
Affiliation:
|
University of Colorado at Denver School of Medicine, Aurora, CO 80045, USA. leigh.perreault@ucdenver.edu |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00795275 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Blood Glucose / analysis Body Mass Index C-Peptide / blood Dipeptidyl-Peptidase IV Inhibitors / adverse effects, therapeutic use* Female Glucagon-Like Peptide 1 / blood, physiology Glucose / chemistry, pharmacokinetics Glucose Tolerance Test Humans Hyperglycemia / blood, drug therapy* Incretins / blood, physiology* Insulin / blood, secretion* Insulin Resistance Insulin-Secreting Cells / drug effects*, secretion Liver / drug effects*, physiopathology Male Middle Aged Pyrazines / adverse effects, therapeutic use* Severity of Illness Index Triazoles / adverse effects, therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
RR-0036/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/C-Peptide; 0/Dipeptidyl-Peptidase IV Inhibitors; 0/Incretins; 0/Pyrazines; 0/Triazoles; 0/sitagliptin; 11061-68-0/Insulin; 50-99-7/Glucose; 89750-14-1/Glucagon-Like Peptide 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-sta...
Next Document: Association between ethnicity and prostate cancer outcomes across hospital and surgeon volume groups...